Compare $BCLI vs $TOVX | Chartloom

Compare

$BCLI vs $TOVX

Brainstorm Cell Therapeutics Inc · Theriva Biologics Inc

BCLI

Brainstorm Cell Therapeutics Inc

TOVX

Theriva Biologics Inc

Compare $BCLI vs $TOVX

Comparing Brainstorm Cell Therapeutics Inc and Theriva Biologics Inc

BCLIBrainstorm Cell Therapeutics Inc

TOVXTheriva Biologics Inc

BCLIBrainstorm Cell Therapeutics Inc

Market cap

$10M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

54.9%

52W performance

30.1%

FCF yield

-21.1%

TOVXTheriva Biologics Inc

Market cap

$10M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-16.5%

52W performance

-51.8%

FCF yield

-128.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

BCLI

TOVX

Detailed metrics comparison

BCLI

Brainstorm Cell Therapeutics Inc

TOVX

Theriva Biologics Inc

Market Cap

BCLI$10M

TOVX$10M

Enterprise Value

BCLI$12M

TOVX$275K

Price

BCLI$0.95

TOVX$0.22

P/E Ratio

BCLIN/A

TOVXN/A

P/S Ratio

BCLI0.00x

TOVX33.19x

EV/Sales

BCLI0.00x

TOVX0.92x

EV/EBITDA

BCLI0.00x

TOVX0.00x

P/B Ratio

BCLI7.31x

TOVX0.85x

P/FCF Ratio

BCLIN/A

TOVXN/A

EV/FCF

BCLI-5.29x

TOVX-0.02x

PEG Ratio

BCLIN/A

TOVXN/A

Forward P/E (NTM)

BCLIN/A

TOVXN/A

Forward P/S (NTM)

BCLIN/A

TOVXN/A

Revenue (TTM)

BCLI$0

TOVX$300K

Revenue Growth (YoY)

BCLIN/A

TOVXN/A

Forward Rev Growth

BCLI53.7%

TOVX20375.2%

Gross Margin (TTM)

BCLI0.0%

TOVX71.5%

Operating Margin (TTM)

BCLI0.0%

TOVX0.0%

EBITDA Margin (TTM)

BCLI0.0%

TOVX-3940.7%

Net Margin (TTM)

BCLI0.0%

TOVX-4376.0%

FCF Margin (TTM)

BCLIN/A

TOVX-4254.7%

Net Income (TTM)

BCLI$-7M

TOVX$-13M

FCF (TTM)

BCLI$-2M

TOVX$-13M

EPS (TTM)

BCLI-$0.61

TOVX-$0.29

ROE (TTM)

BCLI-23636.0%

TOVX-9349.0%

ROA (TTM)

BCLI-33822.0%

TOVX-3269.0%

ROIC (TTM)

BCLI-23636.0%

TOVX-8231.0%

Cash

BCLI$22K

TOVX$11M

Debt

BCLI$1M

TOVX$2M

Net Cash/Debt

BCLI$-1M

TOVX$10M

Current Ratio (TTM)

BCLI0.21x

TOVX1.13x

Quick Ratio (TTM)

BCLI0.16x

TOVX1.09x

Debt/Equity (TTM)

BCLI0.00x

TOVX0.14x

Debt/Assets (TTM)

BCLI0.0%

TOVX0.0%

Interest Coverage (TTM)

BCLIN/A

TOVXN/A

Net Debt/EBITDA (TTM)

BCLI0.00x

TOVX0.00x

Beta

BCLI0.39

TOVX1.25

52W Performance

BCLI30.1%

TOVX-51.8%

YTD Performance

BCLI54.9%

TOVX-16.5%

% from 52W High

BCLI-43.8%

TOVX-74.8%

% from 52W Low

BCLI106.9%

TOVX35.6%

Asset Turnover (TTM)

BCLI0.00x

TOVX0.01x

FCF Yield (TTM)

BCLI-21.1%

TOVX-128.2%

Earnings Yield (TTM)

BCLI-64.2%

TOVX-131.8%

Dividend Yield (TTM)

BCLIN/A

TOVXN/A

Rule of 40

BCLI0.0

TOVX-4,254.7

EV/GP/RG

BCLIN/A

TOVX0.00

Ticker research

View BCLI research View TOVX research

Metric	BCLI Brainstorm Cell Therapeutics Inc	TOVX Theriva Biologics Inc
Market & Valuation
Market Cap	$10M	$10M
Enterprise Value	$12M	$275K
Price	$0.95	$0.22
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	33.19x
EV/Sales	0.00x	0.92x
EV/EBITDA	0.00x	0.00x
P/B Ratio	7.31x	0.85x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.29x	-0.02x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$300K
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	53.7%	20375.2%
Profitability
Gross Margin (TTM)	0.0%	71.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-3940.7%
Net Margin (TTM)	0.0%	-4376.0%
FCF Margin (TTM)	N/A	-4254.7%
Net Income (TTM)	$-7M	$-13M
FCF (TTM)	$-2M	$-13M
EPS (TTM)	-$0.61	-$0.29
ROE (TTM)	-23636.0%	-9349.0%
ROA (TTM)	-33822.0%	-3269.0%
ROIC (TTM)	-23636.0%	-8231.0%
Financial Health
Cash	$22K	$11M
Debt	$1M	$2M
Net Cash/Debt	$-1M	$10M
Current Ratio (TTM)	0.21x	1.13x
Quick Ratio (TTM)	0.16x	1.09x
Debt/Equity (TTM)	0.00x	0.14x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.39	1.25
52W Performance	30.1%	-51.8%
YTD Performance	54.9%	-16.5%
% from 52W High	-43.8%	-74.8%
% from 52W Low	106.9%	35.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-21.1%	-128.2%
Earnings Yield (TTM)	-64.2%	-131.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-4,254.7
EV/GP/RG	N/A	0.00
Ticker research	View BCLI research	View TOVX research

Valuation

P/S Ratio

BCLI

0.00x

TOVX

33.19x

EV/FCF

BCLI

-5.29x

TOVX

-0.02x

Growth & revenue

Forward Revenue Growth

TOVX

20375.2%

BCLI

53.7%

Profitability & performance

Gross Margin

TOVX

71.5%

BCLI

0.0%

ROE

TOVX

-9349.0%

BCLI

-23636.0%

FCF Yield %

BCLI

-21.1%

TOVX

-128.2%

52-Week Performance

BCLI

30.1%

TOVX

-51.8%

Detailed metrics comparison

BCLI

Brainstorm Cell Therapeutics Inc

TOVX

Theriva Biologics Inc

Market Cap

BCLI$10M

TOVX$10M

Enterprise Value

BCLI$12M

TOVX$275K

Price

BCLI$0.95

TOVX$0.22

P/E Ratio

BCLIN/A

TOVXN/A

P/S Ratio

BCLI0.00x

TOVX33.19x

EV/Sales

BCLI0.00x

TOVX0.92x

EV/EBITDA

BCLI0.00x

TOVX0.00x

P/B Ratio

BCLI7.31x

TOVX0.85x

P/FCF Ratio

BCLIN/A

TOVXN/A

EV/FCF

BCLI-5.29x

TOVX-0.02x

PEG Ratio

BCLIN/A

TOVXN/A

Forward P/E (NTM)

BCLIN/A

TOVXN/A

Forward P/S (NTM)

BCLIN/A

TOVXN/A

Revenue (TTM)

BCLI$0

TOVX$300K

Revenue Growth (YoY)

BCLIN/A

TOVXN/A

Forward Rev Growth

BCLI53.7%

TOVX20375.2%

Gross Margin (TTM)

BCLI0.0%

TOVX71.5%

Operating Margin (TTM)

BCLI0.0%

TOVX0.0%

EBITDA Margin (TTM)

BCLI0.0%

TOVX-3940.7%

Net Margin (TTM)

BCLI0.0%

TOVX-4376.0%

FCF Margin (TTM)

BCLIN/A

TOVX-4254.7%

Net Income (TTM)

BCLI$-7M

TOVX$-13M

FCF (TTM)

BCLI$-2M

TOVX$-13M

EPS (TTM)

BCLI-$0.61

TOVX-$0.29

ROE (TTM)

BCLI-23636.0%

TOVX-9349.0%

ROA (TTM)

BCLI-33822.0%

TOVX-3269.0%

ROIC (TTM)

BCLI-23636.0%

TOVX-8231.0%

Cash

BCLI$22K

TOVX$11M

Debt

BCLI$1M

TOVX$2M

Net Cash/Debt

BCLI$-1M

TOVX$10M

Current Ratio (TTM)

BCLI0.21x

TOVX1.13x

Quick Ratio (TTM)

BCLI0.16x

TOVX1.09x

Debt/Equity (TTM)

BCLI0.00x

TOVX0.14x

Debt/Assets (TTM)

BCLI0.0%

TOVX0.0%

Interest Coverage (TTM)

BCLIN/A

TOVXN/A

Net Debt/EBITDA (TTM)

BCLI0.00x

TOVX0.00x

Beta

BCLI0.39

TOVX1.25

52W Performance

BCLI30.1%

TOVX-51.8%

YTD Performance

BCLI54.9%

TOVX-16.5%

% from 52W High

BCLI-43.8%

TOVX-74.8%

% from 52W Low

BCLI106.9%

TOVX35.6%

Asset Turnover (TTM)

BCLI0.00x

TOVX0.01x

FCF Yield (TTM)

BCLI-21.1%

TOVX-128.2%

Earnings Yield (TTM)

BCLI-64.2%

TOVX-131.8%

Dividend Yield (TTM)

BCLIN/A

TOVXN/A

Rule of 40

BCLI0.0

TOVX-4,254.7

EV/GP/RG

BCLIN/A

TOVX0.00

Ticker research

View BCLI research View TOVX research

Metric	BCLI Brainstorm Cell Therapeutics Inc	TOVX Theriva Biologics Inc
Market & Valuation
Market Cap	$10M	$10M
Enterprise Value	$12M	$275K
Price	$0.95	$0.22
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	33.19x
EV/Sales	0.00x	0.92x
EV/EBITDA	0.00x	0.00x
P/B Ratio	7.31x	0.85x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.29x	-0.02x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$300K
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	53.7%	20375.2%
Profitability
Gross Margin (TTM)	0.0%	71.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-3940.7%
Net Margin (TTM)	0.0%	-4376.0%
FCF Margin (TTM)	N/A	-4254.7%
Net Income (TTM)	$-7M	$-13M
FCF (TTM)	$-2M	$-13M
EPS (TTM)	-$0.61	-$0.29
ROE (TTM)	-23636.0%	-9349.0%
ROA (TTM)	-33822.0%	-3269.0%
ROIC (TTM)	-23636.0%	-8231.0%
Financial Health
Cash	$22K	$11M
Debt	$1M	$2M
Net Cash/Debt	$-1M	$10M
Current Ratio (TTM)	0.21x	1.13x
Quick Ratio (TTM)	0.16x	1.09x
Debt/Equity (TTM)	0.00x	0.14x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.39	1.25
52W Performance	30.1%	-51.8%
YTD Performance	54.9%	-16.5%
% from 52W High	-43.8%	-74.8%
% from 52W Low	106.9%	35.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-21.1%	-128.2%
Earnings Yield (TTM)	-64.2%	-131.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-4,254.7
EV/GP/RG	N/A	0.00
Ticker research	View BCLI research	View TOVX research